Recently added

Bispecific antibodies: advancing precision oncology

Herrera, Mercedes; M. Steiner, Thiago; Pretelli, Giulia; Desai, Jayesh; GARRALDA, Elena; Siu, Lillian (Elsevier, 2024-10)

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

Goyal, Lipika; Valle, Juan W; Morizane, Chigusa; Meric-Bernstam, Funda; Hollebecque, Antoine; Karasic, Thomas; Tabernero, Josep (Taylor & Francis, 2024)

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

Kim, Dong-Wan; Hollebecque, Antoine; Nishino, Kazumi; Rha, Sun Young; Schram, Alison; Macarulla, Teresa (Future Medicine, 2024)

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Naing, Aung; Papadopoulos, Kyriakos P; Pishvaian, Michael; rahma, osama; Hanna, Glenn; GARRALDA, Elena; Saavedra, Omar (BMJ, 2024-05-09)

Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil

Ucha, Jose Maria; García-Galea, Eduardo; Gómez Mugarza, Pablo; MARTINI, Giulia; Balconi, Francesca; Alcaraz Soler, Adriana; Garcia Rodriguez, Ariadna; Elez, Elena; Ros, Javier; Comas Navarro, Raquel; R Castells, Marta; Baraibar, Iosune; Salvà, Francesc; Saoudi Gonzalez, Nadia; Tabernero, Josep (MDPI, 2024-12-12)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Bispecific antibodies: advancing precision oncology

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Bispecific antibodies: advancing precision oncology ﻿

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer ﻿

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions ﻿

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours ﻿

Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil ﻿

Bispecific antibodies: advancing precision oncology

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil